1-3 of 3
Pace Johnston
Close
Sort by
Journal Articles

Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat.

Warren Fiskus, Pace Johnston, Rajeshree Joshi, Rekha Rao, Celalettin Ustun, Anand Jillella, Peter Atadja, Stuart Hwang, Sanjeev Redkar, Kapil N. Bhalla
Journal: Blood
Blood (2008) 112 (11): 3355.
https://doi.org/10.1182/blood.V112.11.3355.3355
Published: 2008
Journal Articles

Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells.

Warren Fiskus, Yongchao Wang, Anand Jillella, Celalettin Ustun, Pace Johnston, Rajeshree Joshi, Rekha Rao, Peter Ataja, Victor Marquez, Kapil N. Bhalla
Journal: Blood
Blood (2008) 112 (11): 3356.
https://doi.org/10.1182/blood.V112.11.3356.3356
Published: 2008
Journal Articles

Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells

Warren Fiskus, Yongchao Wang, Anand Jillella, Pace Johnston, Rajeshree Joshi, Rekha Rao, Eduardo Sotomayor, Jianguo Tao, Peter Atadja, Victor Marqez, Kapil N. Bhalla
Journal: Blood
Blood (2008) 112 (11): 3622.
https://doi.org/10.1182/blood.V112.11.3622.3622
Published: 2008